News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Nicholas L. Teti, Jr. Joins ZARS Pharma's Board of Directors

8/24/2007 2:42:00 PM

SALT LAKE CITY, Aug. 24 /PRNewswire/ -- ZARS Pharma, Inc. announced today that Nicholas L. Teti, Jr. has joined the Company's Board of Directors.

"I am pleased to welcome Nick to the Board of Directors," commented Dr. Theodore Stanley, Founder and Chairman of the Board. "Nick brings valuable pharma experience and business knowledge to ZARS."

"I am delighted to join the ZARS Board of Directors and I am eager to bring my experience with life science companies to this organization," stated Nick Teti.

Mr. Teti has served as Chairman of the Board of Directors and the Chief Executive Officer of Isolagen Inc., a biotechnology company, since June 2006. He served as a director, President, and Chief Executive Officer of Inamed Corporation, a medical device company from July 2001 to March 2006 when it was sold to Allergan Corporation. Previously Mr. Teti served as President and director of Yamanouchi USA, Inc., a division of Yamanouchi Pharmaceuticals Co. Prior to Yamanouchi, Mr. Teti served as President, Chief Executive Officer and Chief Operating Officer of DuPont Pharmaceuticals Company. He received a B.A. in economics and an M.B.A. from St. Joseph's University.

About ZARS Pharma, Inc.

ZARS Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of topically applied drugs using its proprietary drug delivery technologies, with an initial focus on pain management. ZARS has developed a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery (CHADD(TM)) and its phase-changing cream (Peel and DuraPeel(TM)) technologies. The Company's products and product candidates include two products that have been approved for marketing (Pliaglis(TM) and Synera(TM)), one product candidate for which it began Phase 3 clinical trials in the second quarter of 2007 (ThermoProfen(TM)) and two product candidates which are in Phase 1 clinical trials.

ZARS Pharma, Inc.

CONTACT: Gregory S. Ayers, Chief Financial Officer of ZARS Pharma, Inc.,+1-801-350-0202

Read at

comments powered by Disqus